Last updated: February 16, 2026
What is the current status of clinical trials for Solriamfetol?
Solriamfetol (brand name: Sunosi) is approved by the U.S. Food and Drug Administration (FDA) for treating narcolepsy and excessive daytime sleepiness (EDS) in Parkinson’s disease and shift work sleep disorder. Its development phase concluded with FDA approval in 2019.
No active Phase 3 or later clinical trials are publicly registered for Solriamfetol. The drug's efficacy and safety profile has been established through multiple Phase 1 and 2 trials, alongside the pivotal Phase 3 studies conducted prior to approval. Post-market observational studies focus on long-term safety and real-world effectiveness but are not registered as interventional trials.
Key milestones:
- 2019: FDA approval for narcolepsy and EDS associated with Parkinson’s disease
- 2020-2022: Post-approval observational studies on safety and efficacy
- 2023: No new clinical trials registered for additional indications or formulations
How does Solriamfetol compare with other wake-promoting agents?
Solriamfetol is a noradrenaline-dopamine reuptake inhibitor (NDRI), with rapid onset and a favorable side effect profile. It is positioned against modafinil and armodafinil, competing in a market for wake-promoting drugs.
Comparative features:
| Attribute |
Solriamfetol |
Modafinil |
Armodafinil |
| Approval Year |
2019 |
1998 |
2007 |
| Indications |
Narcolepsy, EDS in Parkinson’s |
Narcolepsy, EDS, shift |
Narcolepsy, EDS |
| Duration of Action |
8-10 hours |
10-15 hours |
15 hours |
| Common Side Effects |
Headache, nausea, hypertension |
Headache, nausea, insomnia |
Headache, nausea |
This positioning offers an alternative for patients intolerant to other stimulants, with dosing flexibility and a different side effect profile.
What is the market size and competitive landscape?
The global market for wakefulness-promoting agents was valued at approximately $2.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8% to 2030. This growth driven by increasing diagnoses of sleep disorders, expanding approval indications, and longer disease durations.
Market segments:
- Narcolepsy: Largest segment due to unmet needs
- Shift work sleep disorder: Growing segment, especially in North America and Europe
- Parkinson’s disease-related EDS: Moderate but increasing market share
Competitive landscape:
- Modafinil: Market leader with approximately 60% market share
- Armodafinil: Second place, about 20%
- Solriamfetol: Estimated 10-15% share as of 2023, growing with increased clinician awareness
Sales projections estimate Solriamfetol generating $250-350 million annually by 2027, assuming stabilized market penetration.
What are the projections for Solriamfetol's market growth?
Future growth hinges on several factors:
- Expanded indications: Potential for sleep apnea-related EDS and ADHD, though current data are limited
- Regulatory approvals: No current filings outside FDA approval, but EMA or other agencies could approve supplementary indications
- Insurance coverage: The drug’s reimbursement landscape will influence adoption rates; approvals and formulary inclusions are crucial
Market analysts estimate that by 2030, Solriamfetol's market share could reach 20-25% among wakefulness-promoting drugs, particularly if new indications are approved or if the drug is positioned as a first-line therapy for specific populations.
What are the key risks to market expansion?
- Competition from existing drugs: Modafinil and armodafinil have entrenched positions and generic options
- Safety concerns: Long-term safety data are limited, especially in populations with co-morbidities
- Pricing and reimbursement: High cost or restrictive reimbursement policies will dampen adoption
Potential future developments
Research into combination therapies for sleep disorders and expanded indications such as ADHD or obesity-related EDS could open new avenues. However, no significant clinical trial activity for such indications is underway as of 2023.
Key Takeaways
- Solriamfetol is FDA-approved with no current active clinical trials; its safety profile is well-characterized in the context of existing indications.
- The drug faces competition from modafinil and armodafinil, but offers advantages in onset speed and side effect profile.
- The wakefulness-promoting drug market is expanding, with projections indicating significant growth driven by increasing sleep disorder diagnoses.
- Market penetration is limited but expected to grow, reaching a projected $250-350 million annual revenue by 2027.
- Future growth depends on expanding indications, regulatory filings outside the U.S., and reimbursement strategies.
FAQs
1. Are there any ongoing clinical trials for Solriamfetol?
No current active interventional clinical trials are registered publicly for Solriamfetol beyond the initial approval studies.
2. What are the primary side effects of Solriamfetol?
Common adverse effects include headache, nausea, hypertension, and insomnia. Serious side effects are rare but may involve hypertension and psychiatric disturbances.
3. Can Solriamfetol be used for conditions other than narcolepsy and EDS?
Not currently. Off-label use may occur but lacks clinical trial backing and regulatory approval.
4. How does Solriamfetol’s reimbursement landscape look?
Reimbursement varies by country; in the U.S., commercial insurance and Medicare Part D cover the drug, but prior authorization may be required.
5. What is the outlook for Solriamfetol’s approval in other regions?
No public indications of regulatory filings outside the U.S. as of 2023, but future submissions to EMA and other agencies could expand its global footprint.
Sources
- FDA approval announcement, 2019.
- Market research reports, 2022.
- Clinical trial registries, 2023.
- Comparative drug profile databases.
